Avalo Therapeutics Inc (AVTX)
11.53
-0.48
(-4.00%)
USD |
NASDAQ |
Apr 19, 16:00
11.54
+0.01
(+0.09%)
After-Hours: 20:00
Avalo Therapeutics Revenue (Quarterly): 0.571M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.571M |
| September 30, 2023 | 0.236M |
| June 30, 2023 | 0.643M |
| March 31, 2023 | 0.475M |
| December 31, 2022 | 0.896M |
| September 30, 2022 | 14.95M |
| June 30, 2022 | 1.033M |
| March 31, 2022 | 1.173M |
| December 31, 2021 | 0.219M |
| September 30, 2021 | 1.35M |
| June 30, 2021 | 3.355M |
| March 31, 2021 | 0.473M |
| December 31, 2020 | 1.497M |
| September 30, 2020 | 1.111M |
| June 30, 2020 | 1.338M |
| March 31, 2020 | 2.754M |
| Date | Value |
|---|---|
| December 31, 2019 | 0.5808M |
| September 30, 2019 | 2.201M |
| June 30, 2019 | 1.392M |
| March 31, 2019 | 2.576M |
| December 31, 2018 | -6.314M |
| September 30, 2018 | 4.075M |
| June 30, 2018 | 4.785M |
| March 31, 2018 | 4.483M |
| December 31, 2017 | 2.234M |
| September 30, 2017 | 25.04M |
| June 30, 2017 | 0.1578M |
| March 31, 2017 | 0.3842M |
| December 31, 2016 | 0.181M |
| September 30, 2016 | 0.3215M |
| June 30, 2016 | 0.6505M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.219M
Minimum
Dec 2021
14.95M
Maximum
Sep 2022
1.908M
Average
1.111M
Median
Sep 2020
Revenue (Quarterly) Benchmarks
| Imunon Inc | -- |
| iBio Inc | -- |
| Kodiak Sciences Inc | -- |
| Petros Pharmaceuticals Inc | -0.3643M |
| Ocugen Inc | 6.036M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.168M |
| Total Expenses (Quarterly) | 4.322M |
| EPS Diluted (Quarterly) | -10.19 |
| Enterprise Value | 4.508M |
| Profit Margin (Quarterly) | -1.43K% |
| Earnings Yield | -3.31K% |
| Normalized Earnings Yield | -3239.58 |